{
    "clinical_study": {
        "@rank": "157912", 
        "arm_group": [
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1g/kg of body weight, 1 time intra-abdominal administration at time of surgery"
            }, 
            {
                "arm_group_label": "Amino Acid", 
                "arm_group_type": "Experimental", 
                "description": "1g/kg of body weight, 1 time intra-abdominal administration at time of surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether an amino acid is an effective treatment to\n      prevent abdominal/pelvic scar tissue."
        }, 
        "brief_title": "A Phase I Study For the Reduction of Scar Tissue in Adult Females Undergoing Surgery for an Ectopic Pregnancy", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Pelvic Adhesions", 
        "condition_browse": {
            "mesh_term": [
                "Tissue Adhesions", 
                "Pregnancy, Ectopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects are female\n\n          -  Subjects are 18 years of age or older at the time of consent\n\n          -  Subjects have a BMI between 17 and 35\n\n          -  Subjects or subject's legal representative must have signed informed consent form\n\n          -  Subjects have a preoperative diagnosis of an ectopic pregnancy with ultrasonographic\n             confirmation of absence of an intrauterine ectopic pregnancy\n\n        Exclusion Criteria:\n\n          -  Subjects whose BMI is outside the range of 17 - 35\n\n          -  Subjects participating in another clinical trial with a drug or a device\n\n          -  Subjects who have participated in a clinical trial with a drug or device within 30\n             days prior to this study\n\n          -  Subjects with suspected or diagnosed co-existing intrauterine pregnancy\n\n          -  Subjects with suspected intraabdominal infection\n\n          -  Subjects who are immunocompromised\n\n          -  Subjects diagnosed with cancer\n\n          -  Subjects treated with hemostatic agents (e.g. fibrin sealant, collagen, oxidized\n             cellulose)\n\n          -  Subjects treated with adhesion prevention agents other than the Anti-Adhesion Product\n             (APP) (e.g. Intergel\u00ae Adhesion Prevention Solution, Seprafilm\u00ae Membrane)\n\n          -  Subjects taking anti-epileptic medications\n\n          -  Subjects who have been treated with Methotrexate or other chemotherapeutic agents"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701193", 
            "org_study_id": "ADE001-2011"
        }, 
        "intervention": [
            {
                "arm_group_label": "Amino Acid", 
                "description": "Dipeptide", 
                "intervention_name": "Amino Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "description": "Placebo Comparator", 
                "intervention_name": "Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 3, 2012", 
        "location": {
            "contact": {
                "email": "dominique.singh@usask.ca", 
                "last_name": "Dominique C Singh, RN", 
                "phone": "(306) 292-7756"
            }, 
            "facility": {
                "address": {
                    "city": "Saskatoon", 
                    "country": "Canada", 
                    "state": "Saskatchewan"
                }, 
                "name": "Saskatoon Health Region"
            }, 
            "investigator": {
                "last_name": "Donna Chizen, MD, FRCSC", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Phase I Study of an Amino Acid For the Reduction of Peritoneal Adhesions in Adult Females Undergoing a Laparoscopic Salpingostomy for the Removal of an Ectopic Pregnancy", 
        "overall_contact": {
            "email": "dominique.singh@usask.ca", 
            "last_name": "Dominique C Singh, RN", 
            "phone": "(306) 292-7756"
        }, 
        "overall_official": {
            "affiliation": "University of Saskatchewan", 
            "last_name": "Donna Chizen, MD, FRCSC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adhesion Reduction", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701193"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse events in patients from dose administration to 8-week follow up", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "AdeTherapeutics Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Saskatchewan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AdeTherapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}